



Ref. No.: EIKO/BSE/2024-25/09

Date: 13th May 2024

To,
Corporate Services Department,
BSE Limited,
P J Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.

Scrip Code: 540204

Sub: Nil Statement of Deviation(s) or Variation(s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam

Please find enclosed herewith **Annexure-I**, the Statement of Deviation(s) or Variation(s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. CIR/CFD/CMD1/162/2019 dated 24th December 2019, for the quarter ended 31st March 2024 duly reviewed by the Audit Committee at its meeting held on 13th May 2024.

We hereby confirm that there has been no deviation or variation in the use of proceeds of funds raised through Right Issue.

Kindly take the same into your records.

Thanking you,

For **EIKO LIFESCIENCES LIMITED**

Jaid Kojar
Chief Financial Officer

Enclosed: Annexure I

**Annexure I**

Statement of Deviation / Variation in utilisation of funds raised	
Name of listed entity	Eiko Lifesciences Limited
Mode of Fund Raising	Right Issue
Date of Raising Funds (Date of Allotment)	2 nd August 2023
Amount Raised	₹20,50,44,849
Report filed for Quarter ended	31-03-2024
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	Not Applicable
Objects for which funds have been raised and where there has been a deviation, in the following table	Not Applicable